A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Clinical trial NCT04810078 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04810078
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-21
- Primary completion
- 2025-07-29
- Enrollment
- 681
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.